Zobrazeno 1 - 10
of 314
pro vyhledávání: '"Paul A, Marks"'
Autor:
Michal Mielcarek, Christian Landles, Andreas Weiss, Amyaouch Bradaia, Tamara Seredenina, Linda Inuabasi, Georgina F Osborne, Kristian Wadel, Chrystelle Touller, Rachel Butler, Janette Robertson, Sophie A Franklin, Donna L Smith, Larry Park, Paul A Marks, Erich E Wanker, Eric N Olson, Ruth Luthi-Carter, Herman van der Putten, Vahri Beaumont, Gillian P Bates
Publikováno v:
PLoS Biology, Vol 11, Iss 11, p e1001717 (2013)
Histone deacetylase (HDAC) 4 is a transcriptional repressor that contains a glutamine-rich domain. We hypothesised that it may be involved in the molecular pathogenesis of Huntington's disease (HD), a protein-folding neurodegenerative disorder caused
Externí odkaz:
https://doaj.org/article/36f0a78b62114715a37984063f3cb2d9
Autor:
Michal Mielcarek, Caroline L Benn, Sophie A Franklin, Donna L Smith, Ben Woodman, Paul A Marks, Gillian P Bates
Publikováno v:
PLoS ONE, Vol 6, Iss 11, p e27746 (2011)
Huntington's disease (HD) is a progressive neurological disorder for which there are no disease-modifying treatments. Transcriptional dysregulation is a major molecular feature of HD, which significantly contributes to disease progression. Therefore,
Externí odkaz:
https://doaj.org/article/183395ef96d842eba1aaa51650ae8e97
Publikováno v:
Clinical Cancer Research. 21:2198-2200
The study by Kelly and colleagues, published in the September 1, 2003, issue of Clinical Cancer Research, established the safety and biologic activity of the first-in-class histone deacetylase inhibitor, vorinostat, which was administered intravenous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64926777e492c4268bb01dd1f2f67c84
https://doi.org/10.1158/1078-0432.ccr-14-2556
https://doi.org/10.1158/1078-0432.ccr-14-2556
Autor:
Megan L. Choy, Paul A. Marks, Yuanshan Yao, Won-Seok Ham, Gisela Venta-Perez, Ju-Hee Lee, Nathaniel T. Kim, Ronald Breslow, Lang Ngo, Adaickapillai Mahendran
Publikováno v:
Proceedings of the National Academy of Sciences. 110:15704-15709
Development of isoform-selective histone deacetylase (HDAC) inhibitors is important in elucidating the function of individual HDAC enzymes and their potential as therapeutic agents. Among the eleven zinc-dependent HDACs in humans, HDAC6 is structural
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4506681c4570133fe269dfb5623fe08
https://doi.org/10.1073/pnas.1313893110
https://doi.org/10.1073/pnas.1313893110
Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors
Publikováno v:
Proceedings of the National Academy of Sciences. 108:19629-19634
Histone deacetylase inhibitors (HDACi) are a new group of anticancer drugs with tumor selective toxicity. Normal cells are relatively resistant to HDACi-induced cell death compared with cancer cells. Previously, we found that vorinostat induces DNA b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4543abcfb8faa0f9bb4be18099b258e
https://doi.org/10.1073/pnas.1117544108
https://doi.org/10.1073/pnas.1117544108
Autor:
Paul A. Marks
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms. 1799:717-725
There are eleven zinc dependent histone deacetylases (HDAC) in humans which have histones and many non-histone substrates. The substrates of these enzymes include proteins that have a role in regulation of gene expression, cell proliferation, cell mi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf3a696005b74c24589daabfbd6a5560
https://doi.org/10.1016/j.bbagrm.2010.05.008
https://doi.org/10.1016/j.bbagrm.2010.05.008
Publikováno v:
Proceedings of the National Academy of Sciences. 107:20003-20008
Histone deacetylase 6 (HDAC6) is structurally and functionally unique among the 11 human zinc-dependent histone deacetylases. Here we show that chemical inhibition with the HDAC6-selective inhibitor tubacin significantly enhances cell death induced b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeb36cf61fcb05bd7a0d619a12c04aa3
https://doi.org/10.1073/pnas.1013754107
https://doi.org/10.1073/pnas.1013754107
Autor:
Paul A. Marks
Publikováno v:
Expert Opinion on Investigational Drugs. 19:1049-1066
Histone deacetylase (HDAC) inhibitors are being developed as a new, targeted class of anticancer drugs.This review focuses on the mechanisms of action of the HDAC inhibitors, which selectively induce cancer cell death.There are 11 zinc-dependent HDAC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca86aa7569e529cdc6b7d9c801f9beb5
https://doi.org/10.1517/13543784.2010.510514
https://doi.org/10.1517/13543784.2010.510514
Publikováno v:
Proceedings of the National Academy of Sciences. 107:14639-14644
Histone deacetylase inhibitors (HDACi) developed as anti-cancer agents have a high degree of selectivity for killing cancer cells. HDACi induce acetylation of histones and nonhistone proteins, which affect gene expression, cell cycle progression, cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::920f4a055b8e34538e8bc02d2ce04288
https://doi.org/10.1073/pnas.1008522107
https://doi.org/10.1073/pnas.1008522107
Autor:
W.-S. Xu, Paul A. Marks
Publikováno v:
Journal of Cellular Biochemistry. 107:600-608
The role of histone deacetylases (HDAC) and the potential of these enzymes as therapeutic targets for cancer, neurodegenerative diseases and a number of other disorders is an area of rapidly expanding investigation. There are 18 HDACs in humans. Thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5fc3cd7fab1f1eaf91f9ebd7f2aaa80
https://doi.org/10.1002/jcb.22185
https://doi.org/10.1002/jcb.22185